Valuation: Amgen Inc.

Market Cap 208B 181B 168B 154B 292B 19,844B 296B 1,983B 778B 9,879B 781B 764B 33,126B P/E 2026 *
25.3x
P/E 2027 * 23.2x
Enterprise Value 250B 217B 202B 185B 350B 23,822B 356B 2,380B 934B 11,860B 937B 917B 39,767B EV / Sales 2026 *
6.61x
EV / Sales 2027 * 6.33x
Free-Float
99.78%
Yield 2026 *
2.62%
Yield 2027 * 2.77%
1 day+0.42%
1 week+0.74%
1 month+5.27%
3 months+12.10%
6 months+15.80%
Current year+18.69%
1 week 329.85
Extreme 329.85
349.45
1 month 310.3
Extreme 310.3
349.45
Current year 271.8
Extreme 271.8
349.45
1 year 230
Extreme 230
349.45
3 years 209.6
Extreme 209.6
349.45
5 years 174.58
Extreme 174.58
349.45
10 years 120.65
Extreme 120.65
349.45
Manager TitleAgeSince
Chief Executive Officer 63 30/04/2012
Director of Finance/CFO 62 12/05/2010
Director of Finance/CFO 67 31/12/2019
Director TitleAgeSince
Chairman 63 31/12/2012
Director/Board Member 65 31/12/2011
Director/Board Member 71 31/12/2011
Change 5-day change 1-year change 3-year change Capi.($)
+0.42%+0.74% - - 208B
-0.53%-3.95%+50.70%+153.56% 1,024B
+0.21%-2.68%+53.20%+51.79% 618B
-2.51%-3.25%+28.54%+68.94% 443B
+0.06%-0.42%+37.53%+30.67% 349B
-0.69%-0.30%+13.76%+12.83% 264B
-7.37%-4.40%-0.74%-44.28% 209B
-0.82%+0.70%+15.05%+72.05% 162B
+0.40%+1.92%+6.47%-29.77% 143B
+0.69%+5.19%+47.66%+6.14% 133B
Average -1.01%-0.91%+28.02%+35.77% 371.6B
Weighted average by Cap. -0.88%-2.00%+37.00%+69.65%

Financials

2026 *2027 *
Net sales 37.74B 32.8B 30.53B 28.03B 52.94B 3,602B 53.76B 360B 141B 1,793B 142B 139B 6,013B 38.66B 33.61B 31.28B 28.72B 54.24B 3,691B 55.08B 369B 145B 1,837B 145B 142B 6,161B
Net income 8.21B 7.13B 6.64B 6.1B 11.51B 784B 11.69B 78.28B 30.72B 390B 30.82B 30.15B 1,308B 8.83B 7.68B 7.15B 6.56B 12.39B 843B 12.58B 84.23B 33.06B 420B 33.17B 32.44B 1,407B
Net Debt 41.67B 36.23B 33.72B 30.96B 58.46B 3,978B 59.37B 397B 156B 1,980B 157B 153B 6,641B 36.76B 31.95B 29.74B 27.31B 51.57B 3,509B 52.37B 351B 138B 1,747B 138B 135B 5,858B
Logo Amgen Inc.
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (95.8%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other 4.2%): primarily royalties. The United States account for 71.9% of net sales.
Employees
31,500
Date Price Change Volume
31/07/26 €332.70 +0.42% 866
30/07/26 €331.30 -4.08% 747
29/07/26 €345.40 +0.23% 776
28/07/26 €344.60 +3.51% 665
27/07/26 €332.90 +0.80% 504
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
34
Last Close Price
385.16USD
Average target price
357.03USD
Spread / Average Target
-7.30%

Quarterly revenue - Rate of surprise